ライフサイエンスコーパス: primary antibody

1 n blotting with a dinitrophenylated-specific primary antibody.

2 thin the retina using an anti-cGK I-specific primary antibody.

3 rmed by immunofluorescence using an anti-MCP primary antibody.

4 rmed by immunofluorescence using an antihook primary antibody.

5 5 monoclonal antibody (mAb) was used as the primary antibody.

6 adient manipulation and immobilized with the primary antibody.

7 ondary antibodies specific to each patterned primary antibody.

8 e stained with CTGF and TGF-beta1 polyclonal primary antibodies.

9 sis in which individual sera were tested for primary antibodies.

10 econdary antibodies were added to bind these primary antibodies.

11 ally bound to both mouse IgG1 and rabbit IgG primary antibodies.

12 ng using patient sera/cerebrospinal fluid as primary antibodies.

13 of 5 nm gold-nanoparticles derivatized with primary antibodies.

14 secondary antibodies were then used to mark primary antibodies.

15 ific identifications and cross-reactivity of primary antibodies.

16 improve the utility of some poorly reactive primary antibodies.

17 sera of individual patients were tested for primary antibodies.

18 quitination than p53s with a more wild-type (primary antibody 1620+/pAb240-) conformation.

19 rved that cancer-derived p53s with a mutant (primary antibody 1620-/pAb240+) conformation localized i

20 munolabeled by incubation overnight with the primary antibodies 7G6, a cone-specific antibody; SV2, a

21 chemically by simultaneous staining with two primary antibodies: a phospho-specific primary and norma

22 he surface area to capture a large amount of primary antibodies (Ab1), thus amplifying the detection

23 noparticles (MNPs) for immobilization of the primary antibody (Ab1) and utilized the L@MIL-53(Fe)-NH(

24 ever, our optimization of cholesterol level, primary antibody affinity, and antibody-bead linkage all

25 To understand the importance of primary antibody affinity, we compared a series of point

26 We used primary antibodies against CD3, CD8, CD163, PD-L1, pancy

27 Primary antibodies against inflammatory and proangiogeni

28 sections by using double immunolabeling with primary antibodies against Muller and other retina-speci

29 processed by immunoperoxidase staining with primary antibodies against RANTES, MCP-1, ICAM-1, and LF

30 Infected cells were also labeled with primary antibodies against the virus env surface protein

31 ucts was examined by Western blots using the primary antibody against 71-74 residues of cdLC1.

32 were sectioned, dewaxed, and incubated with primary antibody against TGF-beta(b)1 latency-associated

33 urfaces ready for covalent immobilization of primary antibodies and a strong bonding between PDMS sub

34 cultured, fixed, and incubated with specific primary antibodies and their corresponding labeled secon

35 dsorption was then assessed using a specific primary antibody and a secondary antibody conjugated wit

36 mmobilization of UPEC, bovine serum albumin, primary antibody and Horse Radish Peroxidase (HRP) tagge

37 ic antigen (CEA) was immobilized between the primary antibody and horseradish peroxidase (HRP)-conjug

38 he optimal concentration of coating antigen, primary antibody and secondary antibody.

39 All but two patients made primary antibody and T-cell proliferative responses to a

40 the importance of the connection between the primary antibody and the magnetic bead, we compared brid

41 Both direct (labelled primary antibody) and indirect iSERS staining (unlabelle

42 Appropriate negative (ie, no primary antibody) and positive (ie, tonsil and spleen) c

43 nker chemistries were tried for reacting the primary antibody, and its response to target and nonspec

44 32-specific antibodies: an unlabeled capture primary antibody (Anti-1 degrees Ab) and an electrochemi

45 LPS from various species of bacteria and, as primary antibodies, anti-murein lipoprotein (MLP), pepti

46 The assay employing a primary antibodies arrayed on a CMC surface and detectio

47 ure B cells that express huge repertoires of primary antibodies as diverse immunoglobulin (Ig) heavy

48 globulin-G antibodies, enabling a mixture of primary antibodies binding different epitopes to be used

49 f the particle and "intermediate" views, the primary antibody binding site is near the intersection b

50 Serine 15 (phospho-p53(15)), was captured by primary antibodies bound on magnetic Fe3O4 nanoparticles

51 formed between antigens and their respective primary antibodies by cupric ions at high pH.

52 Besides the initial screening of primary antibodies, collection of several hundreds of sa

53 lationship between cluster structure and the primary antibody-combining regions of the HA protein.

54 ffective and well tolerated in patients with primary antibody defects.

55 therapy in SARS-CoV-2-infected patients with primary antibody defects.

56 Lacking protective antibodies, patients with primary antibody deficiencies (PADs) experience frequent

57 Immune system failure in primary antibody deficiencies (PADs) has been linked to

58 The genetic causes of primary antibody deficiencies and autism spectrum disord

59 -exome sequencing on a pair of siblings with primary antibody deficiencies and identified genetic mut

60 Primary antibody deficiencies are the most common immuno

61 Primary antibody deficiencies represent the most prevale

62 plemented by more detailed incidence data on primary antibody deficiencies, revealing trends in diagn

63 There was an emphasis on research in primary antibody deficiencies.

64 new biomarker sets for further research into primary antibody deficiencies.

65 d conditions that lead to the development of primary antibody deficiencies.

66 knowledge on the pulmonary manifestations of primary antibody deficiency (PAD) syndromes in adults.

67 ough autoimmunity is common in patients with primary antibody deficiency (PAD), it remains unknown wh

68 n associated with infection in patients with primary antibody deficiency (PAD).

69 of the Study of Interstitial Lung Disease in Primary Antibody Deficiency (STILPAD) were included in t

70 The primary antibody deficiency syndromes are a rare group o

71 Agammaglobulinemia is the most profound primary antibody deficiency that can occur due to an ear

72 Fifty-three patients (56%) suffered from primary antibody deficiency, 9 (9.6%) had immune dysregu

73 ated from uncomplicated CVID, other forms of primary antibody deficiency, and healthy controls by a d

74 s, OS and EFS were inferior in patients with primary antibody deficiency, bronchiectasis, prior splen

75 at loss of ARHGEF1 accounts for the observed primary antibody deficiency, which manifests in an inabi

76 al respiration in B cells from patients with primary antibody deficiency.

77 e chronic inflammatory complications in this primary antibody deficiency.

78 er-IgM syndrome type 2 (HIGM2), a rare human primary antibody deficiency.

79 g, and mass cytometry to a large cohort with primary antibody deficiency.

80 ctivate PI3K signaling have been linked to a primary antibody deficiency.

81 etrograde signaling as a disease modifier in primary antibody deficiency.

82 the presence of this organism in 17 (19.3%) primary antibody-deficient (PAD) patients, 4 (5%) adults

83 the loss of ARHGEF1 protein expression in 2 primary antibody-deficient siblings presenting with recu

84 The results suggest that primary antibodies directed against viral nucleoproteins

85 ficiency (CVID) is the commonest symptomatic primary antibody disorder, with monogenic causes identif

86 These primary antibodies displayed evidence of diversity in al

87 agnostic antibody assay was performed with a primary antibody, double-labeled amplicons, and fluoroph

88 ombination with a variety of target-specific primary antibodies, effectively minimizing the use of an

89 The resulting primary antibody elicits an anti-antibody response or an

90 ed by immunohistochemistry and the following primary antibodies evaluation.

91 scent molecule: mouse monoclonal anti-biotin primary antibody (fluorescein), biotin (B-phycoerythrin)

92 Specifically, we used a cocktail of primary antibodies for both epithelial and mesenchymal a

93 -bound tissue sections reacted with specific primary antibodies for rat 5-HT(1B, 1D) and (1F) recepto

94 r (PCa) diagnosis are reported, in which the primary antibody for capture is replaced by a DNA aptame

95 of mouse IgG) decreased the affinity of the primary antibody for DCP-UO22+ by 4-fold.

96 Omission or preadsorption of primary antibodies from the antisera and subsequent incu

97 probings of the same membrane with different primary antibodies (> or = 12) and retention of strong s

98 nti-immune complex (IC) antibody binding the primary antibody-HT-2 toxin complex.

99 The detection of measles-specific primary antibodies (IgG) using electrochemical impedimet

100 or combined with carbon nanotubes (CNTs) for primary antibody immobilization to develop a simple and

101 Primary antibody immunodeficiencies (PIDs) constitute a

102 ombinant human immunoglobulin G1 and used as primary antibodies in enzyme-linked immunosorbent assays

103 Primary antibodies included rabbit anti-mouse iNOS combi

104 ryosectioning and were stained using various primary antibodies, including anti-Lewis MHC class II (O

105 spectrometry to quantitate metal-conjugated primary antibodies incubated in intact tumor tissue slid

106 Applicable to any RBP with available primary antibodies, INSCRIBE enables sensitive capture o

107 Because the performance of primary antibodies is strongly influenced by assay conte

108 isolated compartments: (1) sample well, (2) primary antibody labeling well, (3) secondary antibody l

109 The recent development of large primary antibody libraries enables selection of antibodi

110 Control experiments involved omitting the primary antibodies; no labelling was visible under these

111 Protein target was sandwiched between the primary antibody of HBs (Ab1) immobilized on the MNPs an

112 First, the primary antibody of HBs (Ab1) was immobilized on the sur

113 -decorated universal quantum dots and intact primary antibodies, offers a fast, simple and purificati

114 reparation involving direct hybridization of primary antibody-oligonucleotide conjugates to 3DNA.

115 atively, leverage-the effects of circulating primary antibodies on subsequent naive B cell recruitmen

116 easily and homogeneously coats the specific primary antibody on the polyvinylidene fluoride (PVDF) m

117 nbiased approaches to longitudinally dissect primary antibody, plasmablast, and memory B cell (MBC) r

118 Profiles correlating primary antibody-producing cells with the molecular char

119 Furthermore, mixed BMT reconstituted the primary antibody production in BXSB recipients impressiv

120 Moreover, mixed BMT reconstituted primary antibody production in BXSB recipients, so that

121 this platform will expand the repertoire of primary antibody reagents for multiplexed immunostaining

122 on to diversify the anti-PD1 antibody in the primary antibody repertoire in the mouse models.

123 atic hypermutation in the diversification of primary antibody repertoire in these animals.

124 In the bone marrow, diversity in the primary antibody repertoire is created by the combinator

125 In most vertebrates, a primary antibody repertoire is created through the recom

126 ts suggest that the binding potential of the primary antibody repertoire may be significantly expande

127 The limited primary antibody repertoire uses multiple mechanisms to

128 ugments the recombinational diversity of the primary antibody repertoire.

129 ociated with the structural diversity of the primary antibody repertoire.

130 to drive GALT development and diversify the primary antibody repertoire; however, the molecular mech

131 proaches to evaluate in depth the content of primary antibody repertoires and, ultimately, to study h

132 xons from germline gene segments to generate primary antibody repertoires.

133 to support the development both of a potent primary antibody response and of the germinal center res

134 c T-lymphocyte responses but does affect the primary antibody response and the generation of memory B

135 HIV-1 Envelope (Env) and characterizing the primary antibody response for HIV-1 neutralization.

136 odel of the early events that occur during a primary antibody response to a T cell-dependent antigen.

137 T cell help is selective and limiting to the primary antibody response to influenza virus infection a

138 At the same time, the primary antibody response to the H3N2 challenge virus wa

139 Although the primary antibody response to the PPS14-OVA conjugate exc

140 owing MZ B-cell reconstitution resulted in a primary antibody response, demonstrating that MZ B-cell

141 r efficacy, especially in eliciting a strong primary antibody response.

142 o provide help to wild-type B cells during a primary antibody response.

143 ion of Atg7 (B/Atg7(-/-) mice) showed normal primary antibody responses after immunization against in

144 Children had significantly lower primary antibody responses against SARS-CoV-2 proteins o

145 find that IKKalpha(AA) B cells mount normal primary antibody responses but do not enter germinal cen

146 -70 varied over time, including increases in primary antibody responses late in the disease course.

147 Although BLPs enhanced the primary antibody responses seen in some children with no

148 ith the fusion protein gave rise to enhanced primary antibody responses to gp120, particularly of the

149 Although HIV-1-infected children showed good primary antibody responses to measles vaccine, their rap

150 immunized with NS3-FL developed high-titered primary antibody responses to the NS3 ATPase/ helicase d

151 with azithromycin led to significantly lower primary antibody responses, decreased recall proliferati

152 ity for antigen and complement, and dominate primary antibody responses.

153 either cross-reactive antibodies to SV40 or primary antibodies resulting from SV40 infection.

154 Western blot analysis with the same primary antibody showed a specific positive band for iNO

155 ed with 2,4-dinitrophenylhydrazine (DNPH), a primary antibody specific for the 2,4-dinitrophenol grou

156 trategies are proposed for the validation of primary antibody specificity, selectivity, and reproduci

157 ue and its function in altered and humanized primary antibody structures.

158 ditionally, the FLISA utilizes 100-fold less primary antibody than the conventional immunoassay.

159 UT&Tag-RNA-seq, the tissue is incubated with primary antibodies that target histone modifications, fo

160 endrimers were synthesized and conjugated to primary antibodies that were subsequently used for tissu

161 d to Sepharose beads, is used to capture the primary antibody (the antibody of interest).

162 Using a highly affine anti-DCF primary antibody, the optimized ULISA reached a detectio

163 hile conventional WB requires 0.4 mug of the primary antibody, the proposed technique only uses 4 x 1

164 es and bind to the Fc region of target-bound primary antibodies to amplify signals of low-abundant ta

165 hemistry with double immunolabeling, using a primary antibody to amino acids 1-10 of VEGF, together w

166 ctions between MCMV, a glycoprotein-specific primary antibody to MCMV, and polystyrene bead "anchors,

167 -1)) reducing at the same time the amount of primary antibody used (30,000 vs. 1000 dilution factor).

168 etecting a specific protein of interest with primary antibodies using automated fluorescence microsco

169 High specificity of the primary antibodies was confirmed by isoelectric focusing

170 of the antigens recognized by the monoclonal primary antibodies was further confirmed by Western immu

171 le electrodes on a microfabricated chip, the primary antibody was selectively and covalently attached

172 Primary antibodies were immobilized on a solid substrate

173 Anti-SEB primary antibodies were immobilized onto the CNT surface

174 uidic channel, microarrays of five different primary antibodies were patterned onto a single channel

175 First, specific primary antibodies were separately bound to enzymes in c

176 After all primary antibodies were tested in positive and negative

177 PG21 anti-AR and anti-c-fos primary antibodies were visualized by fluorescence micro

178 ry antibody specific to the Fc region of the primary antibody, were used to affect virus mobility.

179 get-molecule-bound mouse IgG1 and rabbit IgG primary antibodies, whereas the bispecific rILSA, MG1Nb-

180 escribed was blocked by preabsorption of the primary antibodies with antigen.

181 ecificity was tested by preadsorption of the primary antibody with a peptide corresponding to sst2A(3

182 nvolves binding of the target protein with a primary antibody with high affinity and specificity, fol

183 ilized estrogen for the binding sites of the primary antibody, with subsequent revelation using alkal